JPH10265393A - Medicine for preventing and treating porcine epidemic diarrhea - Google Patents
Medicine for preventing and treating porcine epidemic diarrheaInfo
- Publication number
- JPH10265393A JPH10265393A JP9070940A JP7094097A JPH10265393A JP H10265393 A JPH10265393 A JP H10265393A JP 9070940 A JP9070940 A JP 9070940A JP 7094097 A JP7094097 A JP 7094097A JP H10265393 A JPH10265393 A JP H10265393A
- Authority
- JP
- Japan
- Prior art keywords
- milk
- epidemic diarrhea
- virus
- immunized
- yolk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
Description
【０００１】[0001]
【発明の属する技術分野】本発明は豚流行性下痢に対す
る予防および治療を主な目的とする。さらに詳細には、
主に消化管内で増殖する豚流行性下痢ウイルスにより引
き起こされる豚の下痢症の予防および治療に関する。The present invention has as its main object the prevention and treatment of swine epidemic diarrhea. More specifically,
The present invention relates to the prevention and treatment of diarrhea in swine caused by swine epidemic diarrhea virus which mainly grows in the digestive tract.
【０００２】子豚期における下痢症の原因としては豚伝
染性胃腸炎ウイルス、ロタウイルス、豚流行性下痢ウイ
ルスあるいは大腸菌等による単独あるいは複数病原体の
感染に起因している。豚流行性下痢は１９９３年頃から
日本での発生が高まり、１９９６には数万頭の子豚が死
亡している。本病は冬季に発生することが多く、哺乳豚
の発病率は１００％に及ぶことがあり、１０日齢以内の
子豚が感染すると下痢、脱水、母乳摂取不足により死亡
率が大変高くなる。[0002] The cause of diarrhea in the piglet stage is caused by infection of single or multiple pathogens by swine infectious gastroenteritis virus, rotavirus, swine epidemic diarrhea virus, Escherichia coli and the like. Swine epidemic diarrhea has been increasing in Japan since around 1993, and tens of thousands of piglets died in 1996. The disease often occurs in winter, and the incidence of suckling pigs can be as high as 100%. When piglets infected within 10 days of age are infected, diarrhea, dehydration and insufficient milk intake lead to extremely high mortality.
【０００３】[0003]
【従来の技術および発明が解決すべき課題】細菌類に起
因するものについては、該菌に対して有効な抗生物質あ
るいは抗菌剤の投与が広く行われている。ウイルスに起
因するものについては主に母豚をワクチンで免疫するこ
とにより、その母乳を介して特異抗体による感染防御能
を哺乳子豚に付与する方法（受動免疫）が広く行われて
いる。豚流行性下痢に対しても母豚を免疫するワクチン
が最近開発された（例えば、日生研ＰＥＤ生ワクチ
ン）。したがって、本病の流行が予想される地域の農場
あるいは既に発生が認められた農場では予め母豚をワク
チン接種しておくことにより、その発生を防ぐことが期
待できる。しかし、すべての農場でワクチンを使用する
ことは実際上不可能に近い。本病は突発的に発生するこ
とが多く、ワクチン未使用農場において発生後、緊急的
にワクチン接種を実施したとしても、ワクチン効果が現
れるまでには少なくとも１〜２ケ月かかり、その間に分
娩された子豚の多くは発病、死亡することになり、多大
な経済的損失を被る。2. Description of the Related Art With respect to bacteria caused by bacteria, administration of antibiotics or antibacterial agents effective against the bacteria is widely performed. With regard to those caused by the virus, a method (passive immunization) of immunizing a sow mainly with a vaccine so as to impart a protective ability to a suckling piglet with a specific antibody via its breast milk is widely performed. Vaccines that immunize sows also against swine epidemic diarrhea have recently been developed (eg, Nissei Ken PED live vaccine). Therefore, it can be expected that the outbreak of this disease can be prevented by vaccinating mother pigs in advance on a farm in an area where the disease is expected to spread or on a farm where an outbreak has already been observed. However, it is virtually impossible to use vaccines on all farms. This disease often occurs suddenly, and it takes at least 1 to 2 months for vaccine effects to appear even if urgent vaccination is performed after it has occurred on an unvaccinated farm, and the baby was delivered during that time Many piglets become sick and die, and suffer significant economic losses.
【０００４】感染性下痢症の予防には、該病原因子に対
する特異抗体の経口投与が有効であることが報告されて
いる（例えば、北島ら、第８０回「日本畜産学会大会、
講演要旨、１９８８年」）。大腸菌やロタウイルスに対
する特異抗体として牛初乳抗体、卵黄抗体、血清抗体お
よびモノクローナル抗体が報告されている（例えば、Ku
roki, M.らの「Arch. Virol., 138, 143-148, 1994」お
よびBridger らの「Infection and Immunity, 31, 906-
910, 1981 」）。一方、流行性下痢ウイルスに対する特
異抗体の効果についての報告はなく、その有効性および
実用性は全く不明であった。[0004] It has been reported that oral administration of a specific antibody against the causative agent is effective in preventing infectious diarrhea (for example, Kitajima et al., The 80th Annual Meeting of the Japanese Society of Animal Husbandry,
Abstract of the Lecture, 1988 "). Bovine colostrum antibodies, egg yolk antibodies, serum antibodies and monoclonal antibodies have been reported as specific antibodies to E. coli and rotavirus (for example, Ku
Roki, M. et al., "Arch. Virol., 138, 143-148, 1994" and Bridger et al., "Infection and Immunity, 31, 906-
910, 1981 "). On the other hand, there has been no report on the effects of specific antibodies against epidemic diarrhea virus, and its efficacy and practicality were not completely clear.
【０００５】[0005]
【課題を解決するための手段】本発明者らは、豚流行性
下痢ウイルスによって引き起こされる下痢症の予防法、
治療法について検討を重ねた結果、豚流行性下痢ウイル
スを免疫した牛から採取した乳またはその乳成分あるい
は該ウイルスで免疫した鶏から得た全卵、卵黄または卵
黄抗体が有効であることを初めて見出した。Means for Solving the Problems The present inventors have developed a method for preventing diarrhea caused by swine epidemic diarrhea virus,
As a result of repeated investigations on the treatment method, it was the first time that milk collected from cattle immunized with swine epidemic diarrhea virus or its milk components or whole eggs, egg yolk or yolk antibodies obtained from chickens immunized with the virus was effective. I found it.
【０００６】本発明の豚流行性下痢ウイルスに対する特
異抗体を含む牛乳または鶏卵卵黄は、例えばつぎのよう
に製造することができるが、これに限定されるものでは
ない。すなわち、妊娠６〜９ケ月の搾乳牛または採卵鶏
に７〜１４日毎に豚流行性下痢ウイルスを単独またはフ
ロインドコンプリートアジュバントなどのアジュバント
と混合、乳化したものを２〜６回皮下または筋肉内に接
種して免疫を行う。そして特異抗体を含む牛乳、好まし
くは出産後１〜３日の初乳または鶏卵を採取する。接種
量は特に制限されず牛又は鶏を該ウイルスで免疫させる
に十分な量であればよい。[0006] The milk or chicken egg yolk containing the specific antibody against the swine epidemic diarrhea virus of the present invention can be produced, for example, as follows, but is not limited thereto. That is, a milking cow or laying hen of 6 to 9 months of gestation is inoculated subcutaneously or intramuscularly with a swine epidemic diarrhea virus alone or mixed and emulsified with an adjuvant such as Freund's complete adjuvant every 6 to 14 days. And immunize. Then, milk containing the specific antibody, preferably, colostrum or chicken eggs 1 to 3 days after delivery is collected. The amount of inoculation is not particularly limited as long as it is sufficient to immunize cattle or chickens with the virus.
【０００７】該ウイルスで免疫された牛の乳汁または鶏
の卵黄は、該ウイルスに特異的に結合する特異抗体を含
有する。したがって、特異抗体を含有する全乳、脱脂
乳、乳清または牛乳から生成された乳汁抗体ならびに鶏
卵全卵、卵黄または卵黄から生成された鶏卵抗体等いず
れのものでも使用できるので、特に限定されない。[0007] Cow milk or chicken egg yolk immunized with the virus contains specific antibodies that specifically bind to the virus. Accordingly, any antibody such as whole milk, skim milk, whey or milk antibody containing a specific antibody and hen egg antibody produced from whole egg, yolk or yolk can be used.
【０００８】豚流行性下痢ウイルスは腸管上皮細胞内で
増えることから、本病による下痢症の予防、治療効果を
有する本発明の特異抗体を含む牛乳または卵黄は経口投
与が好ましい。本発明の乳または卵黄を経口投与する場
合は液剤、錠剤、カプセル剤、粉剤等の剤形で用いるこ
とができる。また、本発明の特異抗体を含む牛乳または
卵黄の乾燥物を代用乳、人口乳に添加して投与すること
もできる。一般的に乳又は卵黄としての１日の投与量は
０．１〜２０ｍｌ／ｋｇ体重であり、１回あるいはそれ
以上投与される。つぎに実施例によりさらに本発明を説
明する。Since swine epidemic diarrhea virus increases in intestinal epithelial cells, oral administration of milk or egg yolk containing the specific antibody of the present invention, which has the effect of preventing and treating diarrhea caused by this disease, is preferred. When the milk or egg yolk of the present invention is orally administered, it can be used in the form of a liquid, tablet, capsule, powder or the like. In addition, dried milk or egg yolk containing the specific antibody of the present invention can be added to milk replacer and artificial milk for administration. Generally, the daily dose as milk or egg yolk is 0.1 to 20 ml / kg body weight, and is administered once or more. Next, the present invention will be further described with reference to examples.
【０００９】実施例 １ 妊娠８ケ月齢のホルスタイン牛２頭に不活化豚流行性下
痢ウイルスＺ９４Ｐ５株１０8 .75 ＴＣＩ50/ml と等量
のフロインドコンプリートアジュバントを混合、乳化し
たもの３ｍｌを皮下に接種した。さらにウイルス液だけ
を初回免疫後２週間毎に２回同様に接種した。分娩後得
られた初乳を遠心により脂肪を除去し脱脂乳を採取し
た。得られた初乳の抗豚流行性下痢ウイルス中和抗体価
は表１に示す。 表１ 免疫牛初乳の抗豚流行性下痢ウイルス中和抗体価 牛番号 豚流行性下痢中和抗体価 ───────────────────── １ ５１２ ２ ２０４８ ────────────────────[0009] Example 1 Pregnancy 8 month old Holstein two cows in the inactivated porcine epidemic diarrhea virus Z94P5 strain 10 8 .75 TCI 50 / ml and an equal volume Freunds complete adjuvant mixing, an 3ml those emulsified subcutaneously Inoculated. Further, only the virus solution was similarly inoculated twice every two weeks after the first immunization. Fat was removed from the colostrum obtained after parturition by centrifugation, and skim milk was collected. The anti-swine epidemic diarrhea virus neutralizing antibody titer of the obtained colostrum is shown in Table 1. Table 1 Anti-Swine Epidemic Diarrhea Virus Neutralizing Antibody Titer of Bovine Colostrum Bovine No. Swine Epidemic Diarrhea Neutralizing Antibody Titer ───────────────────── 1 512 2 2048 ────────────────────
【００１０】実施例 ２ １０羽の採卵鶏に不活化豚流行性下痢ウイルスＺ９４Ｐ
５株 １０7.75ＴＣＩＤ50/ ｍｌと等量のフロインドコ
ンプリートアジュバントを混合、乳化したもの０．５ｍ
ｌを筋肉内に接種した。５羽は非免疫対照鶏とした。さ
らにウイルス液だけを初回免疫後２週間毎に２回同様に
接種した。最終免疫後２週目に鶏卵を採取し、その鶏卵
卵黄から卵黄リポタンパク質を除去し抗豚流行性ウイル
ス中和抗体価を測定した。結果を表２に示す。 表２ 免疫鶏卵卵黄の抗豚流行性下痢ウイルス中和抗体価 区 鶏番号 豚流行性下痢中和抗体価 ──────────────────────── 免疫区 １ ８０ ２ １６０ ３ １６０ ４ ８０ ５ １６０ ６ ３２０ ７ １６０ ８ ３２０ ９ ３２０ １０ ３２０ ────────────────────── 非免疫区 １１ ＜１０ １２ ＜１０ １３ ＜１０ １４ ＜１０ １５ ＜１０ ──────────────────────Example 2 Inactivated swine epidemic diarrhea virus Z94P in 10 laying hens
5 strains 10 7.75 TCID 50 / ml mixed with an equal amount of Freund's complete adjuvant, emulsified 0.5 m
1 was inoculated intramuscularly. Five were non-immune control chickens. Further, only the virus solution was similarly inoculated twice every two weeks after the first immunization. Two weeks after the final immunization, chicken eggs were collected, the yolk lipoprotein was removed from the egg yolk of the chicken, and the anti-pig endemic virus neutralizing antibody titer was measured. Table 2 shows the results. Table 2 Anti-pig endemic diarrhea virus neutralizing antibody titer of immunized chicken egg yolk Chicken number Swine endemic diarrhea neutralizing antibody titer ─────────────────────── ─Immunated area 1 802 160 3 160 4 805 5 160 6 320 7 160 8 320 20 9 320 10 320 ────────────────────── Non-immunized area 11 < 10 12 <10 13 <10 14 <10 15 <10 ──────────────────────
【００１１】実施例 ３ 実施例１で得られた免疫牛初乳および実施例２で得られ
た免疫鶏卵卵黄それぞれ２ｍｌを豚流行性下痢抗体陰性
母豚から産出された２日齢豚に直接経口投与または代用
乳に添加して３回／日与えた。対照群は、非免疫牛初乳
または非免疫鶏卵卵黄を同様に投与した。初回投与２時
間後に＞１０2 ＩＤ50の豚流行性下痢ウイルスＺ９４Ｐ
５株を経口接種し、攻撃試験を実施した。その後毎日、
臨床症状を２週間観察した。その結果を表３に示す。非
免疫初乳および非免疫卵黄を投与した対照群ではすべて
下痢を発症し、それぞれ４頭中３頭および２頭中２頭が
死亡したのに対し、免疫初乳投与群では４頭中２頭、免
疫卵黄投与群では２頭中１頭が下痢を発症したが、数日
以内に下痢が収まり、すべて生存した。免疫初乳および
免疫卵黄投与による副作用は認められなかった。以上の
成績から明らかなように、非免疫牛初乳または非免疫卵
黄を投与した場合はすべてに下痢の発症が認められ、高
い死亡率であったが、抗豚流行性下痢ウイルス抗体を含
む免疫牛初乳または免疫鶏卵卵黄を投与したものについ
ては、下痢の発症率が低下し、死亡するものは１頭もな
かった。したがって、本発明の抗豚流行性下痢ウイルス
免疫牛初乳および鶏卵卵黄が豚流行性下痢に対する予
防、治療効果を有することが確認された。 表３ 免疫牛初乳および免疫鶏卵卵黄の豚での有効性試験 試験群 供試頭数 下痢発症頭数 死亡頭数 ───────────────────────────── 免疫牛初乳投与群 ４ ２ ０ 免疫鶏卵卵黄投与群 ２ １ ０ 非免疫牛初乳投与群 ４ ４ ３ 非免疫鶏卵卵黄投与群 ２ ２ ２ ────────────────────────────Example 3 2 ml each of the immunized cow colostrum obtained in Example 1 and the immunized chicken egg yolk obtained in Example 2 were directly orally administered to a 2-day-old pig produced from a pig with a negative antibody against swine endemic diarrhea. Dosing or addition to milk replacer was given 3 times / day. The control group was similarly administered non-immunized cow colostrum or non-immunized chicken egg yolk. Two hours after the first administration> 10 2 ID 50 swine epidemic diarrhea virus Z94P
Five strains were orally inoculated and challenged. Every day thereafter,
Clinical symptoms were observed for 2 weeks. Table 3 shows the results. In the control group to which non-immune colostrum and non-immune yolk were administered, all diarrhea occurred, and 3 out of 4 animals and 2 out of 2 animals died, respectively, whereas 2 out of 4 animals in the immunized colostrum administration group. In the immunized yolk-administered group, one out of two animals developed diarrhea, but within a few days the diarrhea subsided and all survived. No side effects due to administration of immunized colostrum or immunized yolk were observed. As is evident from the above results, diarrhea was observed in all cases of non-immunized cow colostrum or non-immunized egg yolk, and a high mortality was observed. The incidence of diarrhea was reduced in cow colostrum or immunized egg yolk-administered animals, and none died. Therefore, it was confirmed that the anti-swine epidemic diarrhea virus-immunized bovine colostrum and chicken egg yolk of the present invention have preventive and therapeutic effects on swine epidemic diarrhea. Table 3 Efficacy test group in immunized bovine colostrum and immunized chicken egg yolk in pigs Number of test animals Number of diarrhea onset Number of dead animals ───────────────────────初 Immunized cow colostrum administration group 4 20 Immunized chicken egg yolk administration group 210 0 Non-immunized cow colostrum administration group 4 4 3 Non-immunized chicken egg yolk administration group 2 2 2 ──────── ────────────────────
Claims (3)
採取した牛乳又はその乳成分を含有することを特徴とす
る、豚流行性下痢ウイルスにより引き起こされる豚下痢
症の予防治療剤。1. A preventive and therapeutic agent for swine diarrhea caused by swine epidemic diarrhea virus, comprising milk collected from cows immunized with the swine epidemic diarrhea virus or a milk component thereof.
生する鶏卵の全卵または卵黄ならびにその成分を含有す
ることを特徴とする、豚流行性下痢ウイルスにより引き
起こされる豚下痢症の予防治療剤。2. A preventive and therapeutic agent for swine diarrhea caused by swine epidemic diarrhea virus, comprising a whole egg or yolk of chicken eggs produced by a chicken immunized with the swine epidemic diarrhea virus and a component thereof. .
抗体を含む牛乳または鶏卵抗体を配合してなる、豚用配
合飼料。3. A mixed feed for pigs comprising a milk or chicken egg antibody containing a specific antibody against swine endemic diarrhea virus.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP9070940A JPH10265393A (en) | 1997-03-25 | 1997-03-25 | Medicine for preventing and treating porcine epidemic diarrhea |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP9070940A JPH10265393A (en) | 1997-03-25 | 1997-03-25 | Medicine for preventing and treating porcine epidemic diarrhea |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH10265393A true JPH10265393A (en) | 1998-10-06 |
Family
ID=13446013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP9070940A Pending JPH10265393A (en) | 1997-03-25 | 1997-03-25 | Medicine for preventing and treating porcine epidemic diarrhea |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH10265393A (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20010037612A (en) * | 1999-10-19 | 2001-05-15 | 이재진 | Feed additive containing the dried powder of egg-yolk antibodies, for prevention and treatment of Porcine diarrhea caused by enterotoxigenic Escherichia coli |
| KR20030012563A (en) * | 2001-08-01 | 2003-02-12 | 주식회사 단바이오텍 | Feed compound for substituting antibiotic |
| WO2003070258A1 (en) * | 2002-02-21 | 2003-08-28 | Lee & Joe Biotech Co. | Anti-white spot syndrome virus igy |
| WO2004105792A1 (en) * | 2003-05-30 | 2004-12-09 | Ghen Corporation | Composition against parvovirus infection |
| KR100492492B1 (en) * | 2002-03-07 | 2005-05-31 | 주식회사 에그 바이오택 | THE PRODUCTION METHOD FOR EGG CONTAINING ANTI-E.coli(K88) IgY, ANTI-E.coli(K99) IgY, ANTI-PEDV IgY AND ANTI-TEGV IgY AND THEREOF EGG |
| KR100956648B1 (en) | 2007-12-18 | 2010-05-10 | (주)양성그린바이오 | Porcine disease of antigen manufacturing process and immune antibody production and composition for add electrolyte prevent disease |
| KR100962236B1 (en) | 2008-04-24 | 2010-06-11 | 경상대학교산학협력단 | Pig feed additive using natural pharmacologicl herb and igy and manufacturing method of that |
| CN102580088A (en) * | 2012-03-26 | 2012-07-18 | 广东紫金正天药业有限公司 | Egg yolk antibody for treating porcine circovirus disease and method for producing compound thereof |
| CN102908619A (en) * | 2011-08-04 | 2013-02-06 | 广州格拉姆生物科技有限公司 | Preparation method of egg yolk antibody injection for treating porcine respiratory syndrome |
| US9701735B2 (en) | 2010-11-23 | 2017-07-11 | Pantheryx, Inc. | Compositions and methods for treatment in broad-spectrum, undifferentiated or mixed clinical applications |
-
1997
- 1997-03-25 JP JP9070940A patent/JPH10265393A/en active Pending
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20010037612A (en) * | 1999-10-19 | 2001-05-15 | 이재진 | Feed additive containing the dried powder of egg-yolk antibodies, for prevention and treatment of Porcine diarrhea caused by enterotoxigenic Escherichia coli |
| KR20030012563A (en) * | 2001-08-01 | 2003-02-12 | 주식회사 단바이오텍 | Feed compound for substituting antibiotic |
| WO2003070258A1 (en) * | 2002-02-21 | 2003-08-28 | Lee & Joe Biotech Co. | Anti-white spot syndrome virus igy |
| KR100492492B1 (en) * | 2002-03-07 | 2005-05-31 | 주식회사 에그 바이오택 | THE PRODUCTION METHOD FOR EGG CONTAINING ANTI-E.coli(K88) IgY, ANTI-E.coli(K99) IgY, ANTI-PEDV IgY AND ANTI-TEGV IgY AND THEREOF EGG |
| WO2004105792A1 (en) * | 2003-05-30 | 2004-12-09 | Ghen Corporation | Composition against parvovirus infection |
| KR100956648B1 (en) | 2007-12-18 | 2010-05-10 | (주)양성그린바이오 | Porcine disease of antigen manufacturing process and immune antibody production and composition for add electrolyte prevent disease |
| KR100962236B1 (en) | 2008-04-24 | 2010-06-11 | 경상대학교산학협력단 | Pig feed additive using natural pharmacologicl herb and igy and manufacturing method of that |
| US9701735B2 (en) | 2010-11-23 | 2017-07-11 | Pantheryx, Inc. | Compositions and methods for treatment in broad-spectrum, undifferentiated or mixed clinical applications |
| US10611828B2 (en) | 2010-11-23 | 2020-04-07 | Pantheryx, Inc. | Compositions and methods for treatment in broad-spectrum, undifferentiated or mixed clinical applications |
| CN102908619A (en) * | 2011-08-04 | 2013-02-06 | 广州格拉姆生物科技有限公司 | Preparation method of egg yolk antibody injection for treating porcine respiratory syndrome |
| CN102580088A (en) * | 2012-03-26 | 2012-07-18 | 广东紫金正天药业有限公司 | Egg yolk antibody for treating porcine circovirus disease and method for producing compound thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10973918B2 (en) | Composition and methods for treating acute diarrhea and enteric infections in animals | |
| JPH0753669B2 (en) | Material containing specific antibody from hen's egg, production method and use thereof | |
| JPH10265393A (en) | Medicine for preventing and treating porcine epidemic diarrhea | |
| US10583189B2 (en) | Emulsified vaccine to obtain formulations of concentrated IgY immunoglobulins; processes and uses for the same | |
| Özpinar et al. | Dose-dependent effects of specific egg-yolk antibodies on diarrhea of newborn calves | |
| US20070264264A1 (en) | Method and composition for conferring immunity in mammals | |
| RU2723709C1 (en) | Method for prevention of rota-, coronaviral infection and cattle colibacillosis | |
| EP0839050B1 (en) | Method of enhancing cell mediated immune responses | |
| KR20060025519A (en) | Immunogen adherence and method of making and using same | |
| SK147598A3 (en) | Biological product for preventive or therapeutic oral administration against canine parvovirosis | |
| US20210252148A1 (en) | Composition and Methods for Preventing and Treating African Swine Fever in Wild and Domestic Swine | |
| RU2678132C2 (en) | Canine health product containing antibodies against canine parvovirus type 2 | |
| KR102151962B1 (en) | Method for producing serum composition for preventing or treating infectious disease in young mammal, serum composition produced by the same method, and uses thereof | |
| Ploeger et al. | Production of dairy replacement stock in relation to level of exposure to gastrointestinal nematode infection in the first grazing season: second-year calves and heifers | |
| WO1996010420A1 (en) | Composition and treatment for hyperimmunization with non heat-killed bacteria | |
| Gough et al. | Lactogenic immunity to transmissible gastroenteritis virus induced by a subunit immunogen | |
| US7790178B2 (en) | Trivalent vaccine with maternal anitbody transfer via the milk | |
| RU2357755C2 (en) | Inactivated vaccine against porcine transmissible gastroenteritis (ptge) and porcine epidemic diarrhea (ped) from enteric virus of artificially infected colostrum-free pigs (ptge/ped vaccine) | |
| JPH0665101A (en) | Method for controlling viral disease in salmon/trout using specific antibody-bearing egg | |
| Vihan | Use of Escherichia coli vaccine for passive protection against neonatal colibacillosis in goats | |
| RU2035190C1 (en) | Method of viral disease prevention in agriculture animals | |
| Barman et al. | Elimination of enterotoxigenic Escherichia coli in experimentally infected piglets by passive immunization with bovine colostral antibodies. | |
| JP2004352693A (en) | Anti-parvovirus infection composition | |
| RU2317826C1 (en) | Method for preventing myxomatosis in rabbits | |
| KR19990079333A (en) | Oral immunization for yolk antibody for the prevention and treatment of swine pandemic diarrhea |